Descripción de la empresa
Inventiva S.A. operates as a clinical-stage biopharmaceutical entity dedicated to the development and commercialization of oral small molecule therapies designed to treat metabolic dysfunction-associated steatohepatitis (MASH) and other diseases within the France market and internationally. The company functions within the Healthcare sector, specifically under the Biotechnology industry, where it focuses on advancing novel pan-peroxisome proliferator-activated receptor (PPAR) agonists like Lanifibranor through clinical trials. Inventiva S.A. currently holds a market capitalization of $1.11 billion, while reporting annual revenue of $7.93 million for the trailing twelve months, and the specific count of its employees is not disclosed in the available data. These financial metrics indicate that the company is a mid-sized biotechnology firm with a relatively small revenue base relative to its market capitalization, suggesting a valuation model that heavily discounts future potential clinical outcomes rather than current cash flows. The disparity between the $1.11 billion market cap and the $7.93 million revenue highlights the speculative nature of clinical-stage biotech assets, where the market price primarily reflects the perceived value of the drug pipeline rather than established commercial performance.
Salud financiera
The company reported a revenue of $7.93 million for the trailing twelve months, yet this income figure contrasts sharply with a net income of -$354,137,984 and an EBITDA of -$138,856,000 for the same period. This substantial gap between positive revenue and deeply negative net income reveals a cost structure dominated by high research and development expenses typical of clinical-stage development, where significant capital is consumed by trial costs before any commercial product is available. The free cash flow is not available in the provided financial statements, which implies that the company is in a cash-burning phase common for biotechs in late-stage development, lacking the liquidity to fund operations without external capital raises or strategic partnerships. All three margin metrics reflect this aggressive burn rate, with a gross margin of 100.0% indicating that cost of goods sold is negligible or zero relative to sales, while the operating margin stands at -3686.1% and the profit margin at 0.0%, both signaling severe operational losses that dilute profitability before interest and taxes. The balance sheet position regarding liquidity and leverage is unclear because the specific figures for total cash, total debt, and the debt-to-equity ratio are not provided in the available data. Similarly, the current ratio, which measures short-term liquidity, is not available, preventing an assessment of the company's ability to cover immediate obligations with current assets. Furthermore, the return on equity and return on assets are not available, meaning that management effectiveness in generating returns on shareholder capital or total assets cannot be quantitatively evaluated based on the current financial snapshot.
Evaluación de valoración
The valuation metrics for Inventiva S.A. present a complex picture, with a trailing P/E ratio not available due to the negative earnings, while the forward P/E stands at -4.20, implying that the market expects earnings to remain negative in the near term or that the denominator is still negative in future projections. The price-to-book ratio is listed at -72.83, a negative figure that technically indicates the market price is below the book value of shareholders' equity, though such a negative ratio in a biotech context often reflects the difficulty in valuing intangible assets and future pipeline potential against historical accounting book values. The price-to-sales ratio is significantly elevated at 139.90, suggesting that the market is pricing the company at roughly 140 times its annual revenue, a multiple that prioritizes the potential of its Lanifibranor asset over current sales performance. The enterprise value-to-EBITDA is not available, but the combination of the negative forward P/E and high price-to-sales ratio suggests a valuation driven entirely by the success of upcoming clinical trials rather than fundamental earnings multiples. Regarding trading range, the 52-week high is $7.98 and the 52-week low is $2.85; without the current share price explicitly stated as a variable to calculate a percentage, the stock trades within a historical range where the upper limit represents a roughly 175% gain over the lower limit, illustrating significant volatility typical of small-cap biotechnology stocks. The beta value is 0.95, indicating that the stock's price volatility is nearly identical to the broader market, moving in tandem with the S&P 500 rather than exhibiting the extreme beta values often seen in speculative biotech firms.
Growth & Income
The growth profile of Inventiva S.A. is characterized by a revenue growth rate of -79.6% year over year, while earnings growth is not available due to the lack of comparable positive earnings in the prior period. The negative revenue growth suggests a contraction in sales, likely due to the early commercialization phase where sales are minimal compared to the massive upfront costs of development, rather than a loss of market share. Since the company does not pay a dividend, as evidenced by the dividend yield being not available and a payout ratio of 0.0%, all available cash flow is theoretically reinvested back into the company to fund research, development, and clinical trials rather than being distributed to shareholders. Consequently, the overall growth and income profile is defined by a lack of current profitability and dividend income, relying instead on the potential for future clinical approvals to transform the company's financial trajectory from a cash-burn entity to a commercial revenue generator.